Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma

• Maxime Fayon,
• Carolina Martinez-Cingolani,
• Audrey Abecassis,
• Nathalie Roders,
• Elisabeth Nelson,
• Caroline Choisy,
• Alexis Talbot,
• Armand Bensussan,
• Jean-Paul Fermand,
• Bertrand Arnulf,
• Jean-Christophe Bories

Affiliations

Maxime Fayon

Institut de recherche Saint-Louis, Inserm U976;

Carolina Martinez-Cingolani

Institut de recherche Saint-Louis, InsermU976;

Audrey Abecassis

Institut de recherche Saint-Louis, Inserm U976;

Nathalie Roders

Institut de recherche Saint-Louis, Inserm U976;

Elisabeth Nelson

Institut de recherche Saint-Louis, Inserm U976;

Caroline Choisy

Institut de recherche Saint-Louis, Inserm U976;

Alexis Talbot

Immunology-Haematology department, Hôpital Saint-Louis, AP-HP

Armand Bensussan

Institut de recherche Saint-Louis, Inserm U976;

Jean-Paul Fermand

Immunology-Haematology department, Hôpital Saint-Louis, AP-HP

Bertrand Arnulf

Immunology-Haematology department, Hôpital Saint-Louis, AP-HP

Jean-Christophe Bories

Institut de recherche Saint-Louis, Inserm U976;